Metagenomi Therapeutics, Inc. 8-K

What Happened
Metagenomi Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 in an 8-K filed May 11, 2026. The company furnished a press release with the results and a May 2026 corporate presentation under Regulation FD; the Form 8-K was signed by President and CEO Jian Irish, Ph.D., M.B.A.

Key Details

• Filing date: May 11, 2026; reporting period: quarter ended March 31, 2026 (Item 2.02).
• Press release with the earnings announcement furnished as Exhibit 99.1.
• Corporate presentation dated May 2026 furnished as Exhibit 99.2 (Item 7.01, Regulation FD disclosure).
• The Form 8-K includes the interactive XBRL cover page (Exhibit 104) and is signed by CEO Jian Irish.

Why It Matters
This filing provides investors with the company’s latest quarterly results and accompanying corporate presentation—primary sources for revenue, expense, cash position, and business updates. Because the 8-K furnishes the press release and presentation rather than containing detailed results in the filing text, retail investors should review Exhibits 99.1 and 99.2 for the specific financial figures and operational commentary.